ArticleMolecular biology reports2026
CRIP1 knockdown enhances glycolytic dependence and increases sensitivity to 2-Deoxy-D-Glucose in acute myeloid leukemia.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute Myeloid Leukemia (AML) is an aggressive hematologic malignancy with suboptimal treatment outcomes, necessitating the development of novel therapeutic strategies. Metabolic reprogramming, particularly a dependency on glycolysis, is a hallmark of cancer cells. The cysteine-rich intestinal protein 1 (CRIP1) gene exhibits dual roles in cancer, but its function in AML metabolism remains unexplored. This study investigated the metabolic consequences of CRIP1 knockdown and the subsequent efficacy of the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) compared to the oxidative phosphorylation (OXPHOS) inhibitor IACS-010759.
methodsStable CRIP1 knockdown (CRIP1-KD) was established in the OCI-AML3 cell line using lentiviral shRNA. Metabolic changes were assessed by measuring glucose consumption and lactate secretion. Expression of lactate dehydrogenase A (LDHA) was evaluated by Western blot. The cytotoxic effects of 2-DG and IACS-010759 were determined via flow cytometry using 7-AAD staining.
resultsCRIP1-KD cells demonstrated an 87% reduction in CRIP1 expression (*p*<0.001) and a significant increase in both glucose uptake (*p*=0.04) and lactate production (*p*=0.01) compared to scramble control (SCR) cells. This glycolytic phenotype was corroborated by a 3.3-fold upregulation in LDHA protein expression. Treatment with 2-DG resulted in a more pronounced suppression of glucose consumption and lactate production than IACS-010759 in CRIP1-KD cells (*p*=0.01). Consequently, CRIP1-KD cells exhibited significantly higher cell death after 2-DG treatment (29.10%) compared to IACS-010759 treatment (17.25%; *p*=0.003).
conclusionOur findings indicate that CRIP1 knockdown induces a glycolytic switch in AML cells, rendering them exquisitely sensitive to glycolytic inhibition by 2-DG. This suggests that CRIP1 status could serve as a biomarker for predicting response to metabolic therapies and highlights 2-DG as a promising therapeutic agent for a subset of AML characterized by glycolytic dependency.
Indexed as
Identifiers
41670839What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.